Terazosin
Terazosin, Tezruly (terazosin) is a small molecule pharmaceutical. Terazosin was first approved as Hytrin on 1987-08-07. It is used to treat hypertension, prostatic hyperplasia, and urinary retention in the USA. The pharmaceutical is active against alpha-1A adrenergic receptor, alpha-1B adrenergic receptor, and alpha-1D adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Terazosin, Tezruly (discontinued: Hytrin, Terazosin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Terazosin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TEZRULY | Novitium Pharma | N-218139 RX | 2024-07-29 | 1 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| terazosin | ANDA | 2025-09-30 |
| terazosin hydrochloride | ANDA | 2025-09-30 |
| terazosin hydrochloride terazosin hydrochloride | ANDA | 2019-12-23 |
| tezruly | New Drug Application | 2025-04-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypertension | EFO_0000537 | D006973 | I10 |
| urinary retention | — | D016055 | R33 |
| prostatic hyperplasia | EFO_0000284 | D011470 | N40 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | — | — | 2 | 7 | 9 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | 2 | 1 | 3 | 6 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | 3 | 1 | 1 | — | 5 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | 1 | — | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 1 | 1 | — | 2 |
| Hyperhidrosis | D006945 | — | — | — | — | — | 1 | 1 | 2 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | 1 | — | 1 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | — | 1 | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | 1 | — | 1 |
| Gait analysis | D000077107 | — | — | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | — | 1 |
| Hypercholesterolemia | D006937 | — | — | — | — | 1 | — | — | 1 |
| Coronary disease | D003327 | — | — | — | — | 1 | — | — | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | — | — | 1 |
| Hyperaldosteronism | D006929 | — | E26 | — | — | 1 | — | — | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 1 | — | — | 1 |
| Cerebral hemorrhage | D002543 | — | — | — | — | 1 | — | — | 1 |
| Ischemic stroke | D000083242 | — | — | — | — | 1 | — | — | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | — | — | 1 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Secondary parkinson disease | D010302 | EFO_1001175 | G21 | — | 2 | — | — | — | 2 |
| Rem sleep behavior disorder | D020187 | EFO_0007462 | G47.52 | — | 2 | — | — | — | 2 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | 2 | — | — | — | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | — | — | — | 1 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | 1 | — | — | — | 1 |
| Dyssomnias | D020920 | — | — | — | 1 | — | — | — | 1 |
| Parasomnias | D020447 | — | G47.5 | — | 1 | — | — | — | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | — | 1 |
| Traumatic stress disorders | D040921 | — | — | — | 1 | — | — | — | 1 |
| Lewy body disease | D020961 | EFO_0006792 | G31.83 | 1 | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Ejaculation | D004542 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperplasia | D006965 | EFO_0000536 | — | — | — | — | — | 6 | 6 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | — | — | — | — | 1 | 1 |
| Nocturia | D053158 | — | R35.1 | — | — | — | — | 1 | 1 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | — | — | — | 1 | 1 |
| Pheochromocytoma | D010673 | — | — | — | — | — | — | 1 | 1 |
| Urinary retention | D016055 | — | R33 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Terazosin |
| INN | terazosin |
| Description | Terazosin is a member of quinazolines, a member of piperazines, a member of furans and a primary amino compound. It has a role as an antineoplastic agent, an antihypertensive agent and an alpha-adrenergic antagonist. |
| Classification | Small molecule |
| Drug class | antihypertensives (prazosin type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC |
Identifiers
| PDB | — |
| CAS-ID | 63590-64-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL611 |
| ChEBI ID | 9445 |
| PubChem CID | 5401 |
| DrugBank | DB01162 |
| UNII ID | 8L5014XET7 (ChemIDplus, GSRS) |
Target
Agency Approved
ADRA1D
ADRA1D
Organism
Homo sapiens
Gene name
ADRA1D
Gene synonyms
ADRA1A
NCBI Gene ID
Protein name
alpha-1D adrenergic receptor
Protein synonyms
adrenergic, alpha -1D-, receptor, adrenergic, alpha-1A-, receptor, Alpha-1A adrenergic receptor, Alpha-1D adrenoceptor, Alpha-1D adrenoreceptor, Alpha-adrenergic receptor 1a
Uniprot ID
Mouse ortholog
Adra1d (11550)
alpha-1D adrenergic receptor (P97714)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Terazosin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,456 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,052 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use